Laigo Bio has completed a €17 million seed financing round to advance its oncology and autoimmune programmes.

The Dutch biotech secured an additional €5.5 million in a second close, including €4 million from new co-lead investor Biovance Capital and €1.5 million from existing investor Kurma Partners.

The funding will be used to progress the company’s targeted protein degradation programmes towards the clinic, with a focus on oncology as well as selected autoimmune and immunology indications.

Laigo is developing bispecific antibody-based approaches designed to degrade disease-causing membrane proteins. Its platform links target proteins to E3 ligases to drive their breakdown via cellular degradation pathways.

The company said the approach could enable targeting of membrane proteins that are difficult to address with conventional therapies, although the programmes remain at a preclinical stage.

Matthew Baker, chief executive officer of Laigo Bio, said: “The second close of our seed financing round further validates the potential of our SureTACs platform and its ability to identify first-in-class dual targeted therapies to redefine the treatment of cancer and autoimmune diseases.”

He added: “The additional investment and support from new co-lead investor Biovance Capital, alongside further funding from our existing co-lead investor Kurma Partners, will accelerate our oncology programs towards the clinic and enhance our discovery efforts in auto-immunity and immunology.”

João Incio, general partner at Biovance Capital, said: “Laigo Bio has shown that its SureTACs degradation technology results in remarkable in vivo and in vitro efficacy, with a high degree of selectivity and improved toxicity and safety.”

He added: “We at Biovance Capital see phenomenal potential in Laigo’s technology and support its commitment to exploring an ever-evolving universe of new targets, including those currently considered undruggable.”

The round builds on an initial close completed in December 2025 and brings total seed funding to €17 million.

Early-stage funding rounds of this size remain common in Europe as investors continue to back platform-based approaches in oncology and immunology. However, the long-term impact will depend on whether Laigo can translate its technology into clinical candidates.

The company joins a growing group of biotech firms developing targeted protein degradation strategies, an area that has attracted increasing investment despite limited clinical validation to date.